India Globalization Capital, Inc. (NYSE: IGC) Positioned to Lead in Phytocannabinoid Pharmaceuticals
A study recently highlighted by the American Epilepsy Society (AES) at its 70th annual meeting focused on the potential of cannabidiol (CBD), a derivative of the cannabis plant, as a promising treatment for reducing both the frequency and severity of seizures in children with drug resistant epilepsies (http://nnw.fm/u3xAh). According to the study, patients who received CBD treatment exhibited over 45 percent mean reduction in seizures, and researchers were outspoken in support of further research. Cannabidiol is the most abundant non-psychoactive cannabinoid found in the cannabis plant. Both anecdotal evidence and pre-clinical research have suggested that CBD may have a broad…